Healthcare Sector Announces Acquisitions and Innovations - Research Report on Synta, Auxilium Pharmaceuticals, Accuray, and

Healthcare Sector Announces Acquisitions and Innovations - Research Report on
             Synta, Auxilium Pharmaceuticals, Accuray, and USANA

Editor Note: For more information about this release, please scroll to bottom

PR Newswire

NEW YORK, November 29, 2013

NEW YORK, November 29, 2013 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Synta
Pharmaceuticals Corp. (NASDAQ: SNTA), Auxilium Pharmaceuticals Inc. (NASDAQ:
AUXL), Accuray Incorporated (NASDAQ: ARAY), IPC The Hospitalist Company, Inc.
(NASDAQ: IPCM), and USANA Health Sciences Inc. (NYSE: USNA). Today's readers
may access these reports free of charge - including full price targets,
industry analysis and analyst ratings - via the links below.

Synta Pharmaceuticals Corp. Research Report

On November 21, 2103, Synta Pharmaceuticals Corp. (Synta) announced two
publications with results demonstrating the activity of ganetespib in
preclinical models and in a clinical treatment setting of triple-negative
breast cancer (TNBC). Synta reported that ganetespib is a potent and selective
inhibitor of the Hsp90 chaperone protein being evaluated in over 25 clinical
trials, including a pivotal Phase 3 trial in non-small cell lung cancer. The
Company informed that the results demonstrate the ability of ganetespib to
down-regulate a number of key proteins involved in tumor growth and
metastasis. According to Synta, results by Synta collaborators at Johns
Hopkins University were published on-line in the Journal of Molecular Medicine
and results by Synta scientists and collaborators at Dana-Farber Cancer
Institute and Duke University were published in Clinical Cancer Research.
Synta further reported that clinical activity was also observed along with a
favorable toxicity profile in two TNBC patients treated with ganetespib
monotherapy in the Company-sponsored ENCHANT-1 Phase 2 trial. The Full
Research Report on Synta Pharmaceuticals Corp. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/8ecc_SNTA

--

Auxilium Pharmaceuticals Inc. Research Report

On November 25, 2013, Auxilium Pharmaceuticals Inc. (Auxilium) announced that
new and updated data were presented from its IMPRESS (The Investigation for
Maximal Peyronie's Reduction Efficacy and Safety Studies) trials, which were
the Phase 3 studies that assessed XIAFLEX (collagenase clostridium
histolyticum or CCH) for the potential treatment of Peyronie's disease (PD).
Auxilium reported that the data were presented at the Sexual Medicine Society
of North America (SMSNA) 19th Annual Fall Scientific Meeting held November 21,
2013 to November 24, 2013 in New Orleans, LA. Adrian Adams, CEO and President
of Auxilium, said, "Auxilium remains committed to addressing the unique and
unmet health needs of men, and we continue to uncover new information that we
believe supports our sBLA for XIAFLEX for the treatment of Peyronie's disease.
We believe that, if approved by the FDA for the treatment of Peyronie's
disease, XIAFLEX has the clinical profile to become an important option in a
therapeutic area that currently has limited treatment options. We continue to
work with the FDA as the agency reviews our sBLA." The Full Research Report on
Auxilium Pharmaceuticals Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/86a4_AUXL

--

Accuray Incorporated Research Report

On November 25, 2013, Accuray Incorporated (Accuray) announced continued
momentum in global adoption of its CyberKnife and TomoTherapy Systems. Accuray
reported that the CyberKnife and TomoTherapy Systems, to date, have been used
in 40 countries to treat patients across the full spectrum of radiation
oncology cases including prostate, lung, liver, breast, and head and neck
cancers. According to the Company, Accuray's newest innovations are the
CyberKnife M6 Series and the TomoTherapy H Series Systems treatment solutions.
The CyberKnife M6 Series offers the ability to deliver high-quality, high-dose
distributions that can be confidently delivered to the patient with extreme
accuracy over a minimum number of treatments, reducing side effects and
preserving patients' quality of life, while the TomoTherapy H Series
facilitates interactive treatment planning for clinicians to make development
of customized plans for a wide range of patients and disease types efficient.
The Full Research Report on Accuray Incorporated - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at:

http://www.analystscorner.com/r/full_research_report/36bf_ARAY

--

IPC The Hospitalist Company, Inc. Research Report

On November 26, 2013, IPC The Hospitalist Company, Inc. (IPC) announced that
Judy Shumway, D.O., was recognized as one of the 2013 Top Hospitalists in the
nation by ACP Hospitalist, a publication of the American College of
Physicians. IPC reported that she was recognized in the November 2013 issue of
the publication. Chairman and CEO Adam Singer said, "We are very proud that
Dr. Shumway has been honored by ACP Hospitalist as one of the country's
preeminent hospitalists. A natural-born leader and mentor to her practice, Dr.
Shumway exemplifies IPC's core values of teamwork and professionalism. She
works tirelessly to achieve superior performance, and she embodies the
commitment of delivering the highest quality of care to her patients." The
Full Research Report on IPC The Hospitalist Company, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:

http://www.analystscorner.com/r/full_research_report/d10a_IPCM

--

USANA Health Sciences Inc. Research Report

On November 26, 2013, USANA Health Sciences Inc. (USANA) announced that the
Company has acquired full membership in the U.K. Direct Selling Association
(DSA). USANA reported that the DSA represents the interests of businesses
engaged in direct sales of consumer goods and is committed to guiding the
direct selling industry. USANA's Deputy General Counsel of International
Markets, Kevin McMurray, said, "The membership process required by the U.K.
DSA is one of the most challenging vetting processes of any country-specific
DSA I have ever encountered. It's not surprising they carry a very high degree
of credibility in the direct selling industry." The Full Research Report on
USANA Health Sciences Inc. - including full detailed breakdown, analyst
ratings and price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/ee40_USNA

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Ananya Ghosh, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

SOURCE Analysts' Corner

Contact: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.